Clopidogrel bisulfate 75MG tablets

Added: Dec 04, 2012 11:18 am The National Acquisition Center intends to issue a Request for Proposal (RFP) VA797P-13-R-0001 under the competitive negotiated procedures for Clopidogrel Bisulfate 75MG Tablets. Please see the items and estimated annual usage listed below. The estimated annual usage includes the Department of Veterans Affairs (VA), Department of Defense (DOD), Indian Health Services (IHS), Bureau of Prisons (BOP) and the Federal Healthcare Center (FHCC). Awards will be made in the aggregate for each product group in this solicitation. Product Groups 1 through 3 represent separate requirements for the purpose of Federal Acquisition Regulation (FAR) Clause 52.217-9, "Option to Extend the Term of the Contract" and FAR Clause 52.233-3, "Service of Protest". The Government may award up to three contracts - one for each identified Product Group. The Government reserves the right not to award a contract on this solicitation should offered prices match or exceed Federal Supply Schedule prices.



In order to be considered for award the offerors shall propose prices for all line items for the base and each option year for all line items identified within a product group or groups proposed. Product Groups 1, 2 consist of one line item each. Group 3 consists of two line items and offerors are asked to propose prices for at least one of the two line items. All offered pricing shall include a 0.50% Cost Recovery Fee (see AS6001). Unit prices offered shall not exceed two decimal places. Proposals that fail to include prices for the base year and option years for the line items proposed shall be rejected and shall receive no further consideration. If the offeror is other than the manufacturer, a letter of commitment from the manufacturer to the offeror or other evidence of an uninterrupted source of supply shall be provided by the offeror before contract award (see AS7001). Otherwise, the offer shall be rejected and shall receive no further consideration.



Products offered must be FDA compliant. Offerors shall provide a National Drug Code (NDC) that is unique to the offering company for each proposed line item (see AS1527). Offers that fail to include NDC(s) unique to the offeror by the solicitation due date shall be rejected and shall receive no further consideration. Tablets/Capsules must be compatible with automated dispensing units (Baxter ATC Canisters, OptiFill etc.) The NAICS code for this procurement is 325412. Any future amendments and other miscellaneous documents will be available electronically for download at www.fedbizopps.gov. No paper copies of this solicitation will be available, and no telephone request for paper copies will be approved. All inquiries and concerns must be addressed in writing to the email address stated herein, Attn: Christine.Szrom@va.gov. The Government anticipates an award date on or before February 15, 2013.



Estimated Quantities are as follows:



Group DESCRIPTION PACKAGE SIZE TOTAL ESTIMATED ANNUAL USAGE

1 CLOPIDOGREL BISULFATE 75MG TAB 30 506,400

2 CLOPIDOGREL BISULFATE 75MG TAB 90 792,934

3A CLOPIDOGREL BISULFATE 75MG TAB 500 39,871

OR OR OR OR

3B CLOPIDOGREL BISULFATE 75MG TAB 1000 18,422